LISATA THERAPEUTICS INC. - COMMON STOCK

3,7300

10-января-25 16:45:00

15 мин. задержка

Акции

-0,0700

-1,84%

Сегодняшний диапазон

3,7000 - 3,9100

ISIN

N/A

Источник

NASDAQ

Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events

08 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

02 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

23 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

09 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

03 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

21 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

29 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

22 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics to Present at BIO CEO & Investor Conference

20 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

17 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

04 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

12 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics to Present at NobleCon19 Investor Conference

28 ноя 2023 16:05:03 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in November

09 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

02 ноя 2023 16:05:01 Источник Nasdaq GlobeNewswire
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

26 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

24 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer

17 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in October

28 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire
Lisata Therapeutics Announces Participation in InfoSec World 2023

20 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.